What is the role of peginesatide (Hematide) in the treatment of anemia of chronic disease and renal failure?

Updated: Apr 13, 2020
  • Author: Gates B Colbert, MD, FASN; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


Peginesatide (Hematide) is a pegylated, peptidic ESA (also called an erythropoietin mimetic [EPO mimetic]) that was approved in the United States in March 2012 for treatment of anemia of chronic kidney disease, but was discontinued in February 2013 following postmarketing reports of severe hypersensitivity, including fatalities. [28] This agent binds to the erythropoietin receptor, thereby activating intracellular signaling pathways. The advantages of peginesatide include low immunogenicity and no structural homology to endogenous or exogenously administered ESAs.

The EMERALD study found that the effectiveness of peginesatide was not inferior to epoetin for patients receiving dialysis. [25] Similarly, the PEARL study found peginesatide was not inferior to darbepoetin for patients with chronic kidney disease who were not receiving dialysis. [28] However, safety endpoints (ie, cardiovascular events and death) were worse for peginesatide than for darbepoetin in the PEARL study.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!